martedì, 21 marzo 2023

Notizie AIOM – anno XV n. 618

28 Febbraio 2017

Effect of Radiotherapy on Painful Bone Metastases. A Secondary Analysis of the NCIC Clinical Trials Group Symptom Control Trial SC.23

Many studies that found improved quality of life (QOL) after radiotherapy of bone metastases have small sample sizes and do not use specific questionnaires. How soon after radiotherapy one can expect an improvement in QOL is unknown. To investigate QOL at days 10 and 42 ...
Leggi tutto

28 Febbraio 2017

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

We performed an individual patient data meta-analysis to examine the impact of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy on overall survival (OS) in advanced non–small cell lung cancer (NSCLC). Data from trials ...
Leggi tutto

27 Febbraio 2017

FDA Approves Maintenance Lenalidomide for Myeloma

February 22nd, 2017 - The FDA has approved lenalidomide as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant (auto-HSCT), according to Celgene, the manufacturer of the treatment. The data for the approval came ...
Leggi tutto

27 Febbraio 2017

EC Approves Maintenance Lenalidomide for Myeloma

February 24th, 2017 - The European Commission has expanded the indication for lenalidomide to include use as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant (auto-HSCT), according to Celgene, the manufacturer ...
Leggi tutto

27 Febbraio 2017

Daratumumab Triplets Recommended for EU Approval in Myeloma

February 24th, 2017 - The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with relapsed multiple myeloma following at ...
Leggi tutto

27 Febbraio 2017

EC Approves Alectinib for ALK+ NSCLC

February 24th, 2017 - The European Commission has approved alectinib as a treatment for patients with metastatic ALK-positive non–small cell lung cancer (NSCLC) following progression on crizotinib, according to Roche, the developer of the second-generation ALK inhibitor. ...
Leggi tutto

27 Febbraio 2017

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials

In cancer clinical trials, symptomatic adverse events (AEs), such as nausea, are reported by investigators rather than by patients. There is increasing interest to collect symptomatic AE data via patient-reported outcome (PRO) questionnaires, but it is unclear whether it ...
Leggi tutto

24 Febbraio 2017

FDA Grants Inotuzumab Ozogamicin Priority Review for ALL

February 21st, 2017 - The FDA has granted a priority review designation to the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia (ALL), based on findings from the phase III INO-VATE ...
Leggi tutto

24 Febbraio 2017

FDA Grants Ceritinib Priority Review in Frontline ALK+ NSCLC

February 23rd, 2017 - The FDA has granted a priority review to ceritinib as a first-line treatment for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC), according to Novartis, the manufacturer of the second-generation ALK inhibitor. The priority ...
Leggi tutto

24 Febbraio 2017

Efficacy of salpingectomy at hysterectomy to reduce the risk of epithelial ovarian cancer: a systematic review

It has been argued that salpingectomy would reduce the risk of epithelial ovarian cancer (EOC), based on the theory of the tube being the site of origin. To conduct a systematic review of 'salpingectomy' associated with ovarian cancer risk and 'salpingectomy with concomitant ...
Leggi tutto